Automated Point Of Care DR Screening
The number of people with vision loss from diabetic retinopathy has grown significantly over the years creating a growing need for expanding DR screening. EyeArt provides fully automated DR screening, including imaging, grading for DR in accordance with internationally recognized standards, and reporting in a single office visit. EyeArt™ is approved by EU as a Class IIa medical device for sales in Europe.Read more
EyeMark consists of a set of tools for automated computation of biomarkers for diabetic retinopathy (DR) using retinal fundus images. Specifically, it computates microaneurysm (MA) appearance and disappearance rates (jointly known as turnover rates) for use as a biomarker in monitoring progression of DR. The availability of a reliable image-based biomarker is expected to have high positive influence on various aspects of DR care, including screening, monitoring progression, drug discovery and clinical research..Read more
Automated AMD Screening
Age-related macular degeneration (AMD) is the single largest cause for legal blindness among senior Americans. Without a straightforward, reliable way to screen for these vulnerable patients, early detection and treatment remains a problem. EyeSeeAMD™ performs a robust, automated screening test for AMD that can be performed by a primary health care provider or an optometrist, who can then refer the patient to an eye specialist, if required.Read more
Fully automate your DR screening with EyeArt™
Imaging, grading for diabetic retinopathy, and reporting in a single office visit.
Diabetic retinopathy, or DR, is a blinding eye disease that can affect more than 415 million diabetic patients worldwide, including more than 29 million people in the US. Vision loss in these patients is preventable, if diagnosed early. But eye care professionals cannot keep pace with the demand for annual screening. EyeArt is what we believe the most advanced technology designed to quickly identify critical DR patients so they can be referred for immediate help.
EyeArt™ Product Highlights• Completely Automated Fully automated DR screening, including imaging, grading for DR in accordance with internationally recognized standards and reporting, in a single office visit. • Extensive Clinical Validation Tested in clinical validation studies on one of the largest data sets of patients of any available DR screening technology, in demanding, real world settings using images captured in everyday practice.• Flexible Design The technology is designed to work effectively with image quality commonly found in diabetes patients and with imaging protocols/cameras typically used in screening setups. • High sensitivity and specificity Demonstrates over 91% screening sensitivity and specificity in a retrospective study of 78,685 consecutive patient visits, with over 98.5% sensitivity in identifying patients with potentially treatable DR.
Clinicians are excited about Eyenuk's upcoming products
"EyeArt could have a huge impact in improving the lives of individuals with diabetes who still face the risk of losing vision asymptomatically."
Prof. Andrew BoultonMD, DSc(Hon), FACP, FRCP
Renowned Diabetes Expert,
Professor of Medicine,
University of Manchester, UK
"I believe that an automated, reliable DR screening tool such as EyeArt would empower primary care providers to better manage their patients and diabetes."
Dr. Srinivas SaddaMD
President and CSO,
Doheny Eye Institute, Los Angeles, USA
"I believe that automation of common tasks like DR screening would have a tremendous impact on the quality and extent of vision care for the disparity populations. Therefore I am eager to work with EyeArt tool for DR screening."Dr. Todd MargolisMD, PhD
Distinguished Professor and Chairman,
Ophthalmology and Visual Sciences Washington University School of Medicine,
St. Louis, MO. (Former President of ARVO)
"...results of the large scale validation on over 75,000 patient encounters from the EyePACS database are highly encouraging and show that EyeArt can be a safe and effective alternative to manual screening."Dr. Jorge CuadrosOD, PhD
Founder, EyePACS Diabetic Blindness Prevention Program,
EyePACS LLC, CA,
Assistant Clinical Professor,
UC Berkeley School of Optometry, CA
"EyeArt’s automatic lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients."Dr. Lauren P. DaskivichMD, MSHS
Director of Ophth. and Eye Health Programs,
LA County Department of Health Services,
Los Angeles, CA
Signup to stay up-to-date on Eyenuk's products!* Products were supported by Award numbers R44EB013585, R42TR000377, R43EY024848, and R43EY025984 from the National Institutes of Health (NIH). The content is solely the responsibility of Eyenuk, Inc. and does not necessariliy represent the official views of NIH. ** The devices are covered by one or more of the following US patents and their foreign counterparts: 8879813, 8885901, 9002085, and 9008391. Additional patents are pending.EyeArt™ has been cleared for sales as a Class IIa medical device by EU In the United States, EyeArt™ is limited by federal law to investigational use only and is not available for sale.EyeMark™, EyeApp™, and EyeSeeAMD™ have not yet been cleared for sales in the US or EU.
© Copyright 2010-2017, Eyenuk Inc.